United Kingdom

Excivion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CPI Partners with Excivion to Optimise and Scale up Production of Safe and Effective Zika Vaccine

Lead Product(s): Zika-HX antigen

Therapeutic Area: Infections and Infectious Diseases Product Name: Zika vaccine

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: CPI

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 13, 2020

Details:

Excivion has partnered with CPI to draw upon the company’s extensive experience in the optimisation and scale-up of biologics manufacturing processes to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX.

Reading Scientific Services

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients

Lead Product(s): Fentanyl

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ethypharm

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 04, 2020

Details:

The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.

Fujifilm Diosynth Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

Lead Product(s): Live modified horsepox virus vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2020

Details:

Under the agreement, Fujifilm Diosynth Biotechnologies will develop a manufacturing process, manufacture, and stock a supply of TNX-1800 at FDB’s College Station, Texas site for Tonix’s clinical development.

GE Healthcare Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines

Lead Product(s): Covigenix

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Entos Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2020

Details:

Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.

ImmuPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immupharma’s Efforts in the Fight Against Covid-19 with Lupuzor™ and Ureka

Lead Product(s): IPP-201101

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Investigation of the application of the Ureka peptide technologies within the Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies.

AI VIVO

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AI VIVO Seeks Collaboration Partners to Progress Top-ranked COVID-19 Therapeutic Candidates

Lead Product(s): Imatinib

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

AI VIVO is seeking pharma and biotech collaboration partners to progress therapeutic candidates that have been identified by the Company as “top-ranked” for COVID-19.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vaccitech and Oxford University Enter Partnership with AstraZeneca To develop and Distribute COVID-19 vaccine candidate

Lead Product(s): COVID 19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Vaccitech Oncology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 30, 2020

Details:

Under the new agreement, AstraZeneca will work with global partners on the international distribution COVID-19 vaccine, to make it available and accessible for low and medium income countries.

Valo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Valo Therapeutics to Support Development of a Pan - Coronavirus Vaccine

Lead Product(s): COVID-19-adenovirus vector-based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Valo Tx's PeptiCRAd technology to coat non-replicating adenovirus expressing COVID-19 Spike, with HLA-matched peptides tailored to boost immune responses of CD8 + T-cells.

Iontas

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FairJourney Biologics and Iontas Announce Partnership in Search for SARS-CoV-2 Treatment

Lead Product(s): Antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: FairJourney Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 16, 2020

Details:

The combination will enable the newly created partnership to isolate highly specific, neutralizing SARS-CoV-2 antibodies displaying high affinity and preferential biophysical characteristics.

GlaxoSmithKline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GSK allies with Innovax for COVID-19 vaccine R&D project

Lead Product(s): AS03,Recombinant protein-based vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Xiamen Innovax Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 03, 2020

Details:

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Excivion

CPI Partners with Excivion to Optimise and Scale up Production of Safe and Effective Zika Vaccine

Reading Scientific Services

Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients

Fujifilm Diosynth Biotechnologies

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

GE Healthcare Inc

Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines

ImmuPharma

Immupharma’s Efforts in the Fight Against Covid-19 with Lupuzor™ and Ureka

AI VIVO

AI VIVO Seeks Collaboration Partners to Progress Top-ranked COVID-19 Therapeutic Candidates

AstraZeneca PLC

Vaccitech and Oxford University Enter Partnership with AstraZeneca To develop and Distribute COVID-19 vaccine candidate

Valo Therapeutics

Valo Therapeutics to Support Development of a Pan - Coronavirus Vaccine

Iontas

FairJourney Biologics and Iontas Announce Partnership in Search for SARS-CoV-2 Treatment

GlaxoSmithKline

GSK allies with Innovax for COVID-19 vaccine R&D project